Contact:
At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992
or
At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672
or
General Inquiries
Kathy Waller
312.640.6696 |
RegeneRx's Chief Executive Interviewed by Wall Street Transcript For Annual Biotechnology Issue
RegeneRx's Chief Executive Interviewed by Wall Street Transcript For Annual Biotechnology Issue
March 2, 2006 — Bethesda, Md
RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) reported today that J.J. Finkelstein, president and chief executive officer, was interviewed by The Wall Street Transcript for its annual biotechnology issue, which was published this week. The full text of the interview may be accessed by clicking on a link on RegeneRx's home page at www.regenerx.com.
The interview addresses the company's technology platform and its ongoing and projected clinical trials. Additionally, Mr. Finkelstein discusses RegeneRx's business model, management, and the company's expectations for 2006.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore RegeneRx is developing TB4 as a therapeutic platform. RegeneRx holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2006 as part of its ongoing clinical development program.
Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development of TB4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.
SOURCE: RegeneRx Biopharmaceuticals, Inc.  Back To 2006 Press Release Archives
|
